BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Hepatol Res 2021. [PMID: 34472683 DOI: 10.1111/hepr.13706] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Seo JY, Cho EJ, Kim MJ, Kwak MS, Yang JI, Chung SJ, Yim JY, Yoon JW, Chung GE. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population. J Cachexia Sarcopenia Muscle 2022. [PMID: 36222309 DOI: 10.1002/jcsm.13099] [Reference Citation Analysis]
2 Ogasawara Y, Kogiso T, Horiuchi K, Taniai M, Tokushige K. Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality.. [DOI: 10.21203/rs.3.rs-2110374/v1] [Reference Citation Analysis]
3 Wen W, Li H, Wang C, Chen C, Tang J, Zhou M, Hong X, Cheng Y, Wu Q, Zhang X, Feng Z, Wang M. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis. Front Endocrinol 2022;13:934225. [DOI: 10.3389/fendo.2022.934225] [Reference Citation Analysis]
4 Tsutsumi T, Nakano D, Kawaguchi M, Hashida R, Yoshinaga S, Takahashi H, Anzai K, Kawaguchi T. MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men. Diabetol Metab Syndr 2022;14:115. [PMID: 35974418 DOI: 10.1186/s13098-022-00887-w] [Reference Citation Analysis]
5 Wajsbrot NB, Leite NC, Salles GF, Villela-Nogueira CA. Non-alcoholic fatty liver disease and the impact of genetic, epigenetic and environmental factors in the offspring. World J Gastroenterol 2022; 28(25): 2890-2899 [DOI: 10.3748/wjg.v28.i25.2890] [Reference Citation Analysis]
6 Lanzaro F, Guarino S, D'Addio E, Salvatori A, D'Anna JA, Marzuillo P, Miraglia del Giudice E, Di Sessa A. Metabolic-associated fatty liver disease from childhood to adulthood: State of art and future directions. World J Hepatol 2022; 14(6): 1087-1098 [DOI: 10.4254/wjh.v14.i6.1087] [Reference Citation Analysis]
7 Rui F, Yang H, Hu X, Xue Q, Xu Y, Shi J, Li J. Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management. Infectious Microbes and Diseases 2022;4:49-55. [DOI: 10.1097/im9.0000000000000089] [Reference Citation Analysis]
8 Tsutsumi T, Kawaguchi T, Nakano D, Torimura T. Atherosclerotic cardiovascular disease in non-metabolic nonalcoholic fatty liver disease. Hepatol Res 2022;52:317-9. [PMID: 35229393 DOI: 10.1111/hepr.13738] [Reference Citation Analysis]
9 Milluzzo A, Manuella L, Cannata E, Russo G, La Vignera S, Purrello F, Di Cataldo A, Sciacca L. Influence of Body Mass Index, Cancer Type and Treatment on Long-Term Metabolic and Liver Outcomes in Childhood Cancer Survivors. J Clin Med 2022;11:878. [PMID: 35160329 DOI: 10.3390/jcm11030878] [Reference Citation Analysis]
10 Chen Y, Yang C, Chung C, Ho C, Chen W, Chien W. The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study. Hepatol Int. [DOI: 10.1007/s12072-021-10281-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
11 Bardales Silva AF. Enfermedad hepática grasa relacionada a trastornos metabólicos. RMB 2022;15:85-93. [DOI: 10.33326/26176068.2021.4.1259] [Reference Citation Analysis]